Picture of Seer logo

SEER — Seer News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousSmall CapNeutral

Life sciences company Seer's Q3 net loss narrows

Overview

Seer Q3 2025 revenue rose 2% yr/yr to $4.1 mln, driven by product and service sales

Net loss for Q3 2025 was $18.2 mln, an improvement from $21.3 mln last year

Company saw robust demand for Proteograph ONE, increasing instrument shipments

Outlook

Seer expects full-year 2025 revenue between $17 mln and $18 mln

Result Drivers

PROTEOGRAPH DEMAND - Robust demand for Proteograph ONE workflow drove increased instrument shipments

PUBLICATION RECORD - Record number of third-party publications validating Proteograph technology

PRODUCT SALES - Higher product sales contributed to revenue growth

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 Revenue$4.12 mln
Q3 EPS-$0.32
Q3 Net Income-$18.23 mln
Q3 Gross Margin51.00%
Q3 Gross Profit$2.11 mln
Q3 Operating Expenses$21.46 mln
Analyst Coverage The one available analyst rating on the shares is "buy" The average consensus recommendation for the office equipment peer group is "buy" Press Release: ID:nGNX6McLPS For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Seer

See all news